BioSight
Companies
AN2 Therapeutics, Inc. logo

ANTX

NASDAQMENLO PARK, CA
AN2 Therapeutics, Inc.

AN2 Therapeutics develops drug candidates for infectious diseases, with a focus on antibacterial therapies. The company is advancing epetraborole, its initial product candidate, through clinical trials and plans to expand into additional patient populations pending regulatory approval. AN2 is in the clinical-stage development phase, conducting preclinical studies and clinical trials while working toward potential regulatory approval in the United States and other territories.

Price history not yet available for ANTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar